Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AMGN v. TKTX: Waiting for Round 2

When attorneys for Amgen Inc. and Transkaryotic Therapies Inc. appear in trial court May 15, the bottom line, at least initially, will be whether TKTX can show that claim one

Read the full 303 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE